Donate
Back to Clinical Trials
Back to Clinical Trials

Brief Title: Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)

INTRODUCTION

  • Org Study ID: UCDCC312
  • Secondary ID: N/A
  • NCT ID: NCT06101290
  • Sponsor: University of California, Davis

BRIEF SUMMARY

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

DETAILED DESCRIPTION

This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary endpoint is disease control at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy. Participants will receive ablative local therapy per standard practices in addition to their systemic therapy and will be followed for up to 5 years following ablative local therapy. Participants will be assigned stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist.

  • Overall Status
    Recruiting
  • Start Date
    October 5, 2023
  • Phase
    Not Applicable
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Prostate Cancer
  • Oligoprogressive
  • Urothelial Carcinoma
  • Renal Cell Carcinoma

ELIGIBILITY

Inclusion Criteria:
1. Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies:
1. Cohort A: prostate cancer

- 2. Cohort B: urothelial carcinoma

- 3. Cohort C: renal cell carcinoma

- 2. Provision of signed and dated informed consent form.

- 3. Stated willingness to comply with all study procedures and availability for the duration of the study.

- 4. Age ≥18 years at time of consent.

- 5. Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.

- 6. ≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]

- 7. ≤ 5 progressing or new metastatic lesions.

- 8. All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.
Exclusion Criteria:
1. Medical comorbidities precluding locally ablative therapies.

- 2. History of treatment related toxicities that limit or prohibit application of locally ablative therapies.

- 3. Progressing intracranial lesions.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Mamta Parikh, MD, MS

Role: Principal Investigator

Affiliation: University of California, Davis

Overall Contact

Name: Selina Laqui

Phone: 916-734-0565

Email: sblaqui@ucdavis.edu

LOCATION

Facility Status Contact
Facility: University of California, Davis
Sacramento, California 95817
United States 		Status: Recruiting Contact: Contact
Selina Laqui
916-734-0565
sblaqui@ucdavis.edu

Principal Investigator
Mamta Parikh, MD, MS

Read Our Stories